The inhibition of metalloproteinases as a therapeutic target in rheumatoid arthritis and osteoarthritis

Current Opinion in Pharmacology

Volumn 1, Issue 3, 2001, Pages 314-320

  Bigg, Heather F ^a   Rowan, A D ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Arthritis; Cartilage; Inhibitor; Metalloproteinase

Indexed keywords

ANTIRHEUMATIC AGENT; METALLOPROTEINASE; PROTEINASE INHIBITOR;

ANIMAL; DRUG ANTAGONISM; HUMAN; OSTEOARTHRITIS; PATHOLOGY; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; METALLOENDOPEPTIDASES; OSTEOARTHRITIS; PROTEASE INHIBITORS;

EID: 0035376862     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(01)00055-8     Document Type: Review

References (59)

1. Hardingham T.E., Fosang A.J. Proteoglycans: many forms and many functions. FASEB J. 6:1992;861-870.
2. Prockop D.J. What holds us together? Why do some of us fall apart? What can we do about it? Matrix Biol. 16:1998;519-528.
3. Eikenberry E.F., Bruckner P. Supramolecular structure of cartilage matrix. Seibel M.J., Robins S.P., Bilezikian J.P. Dynamics of Cartilage and Bone Metabolism. 1999;289-300 Academic Press, San Diego.
4. Shingleton W.D., Hodges D.J., Brick P., Cawston T.E. Collagenase: a key enzyme in collagen turnover. Biochem Cell Biol. 74:1996;759-775.
5. Woessner J.F. Jr, Nagase H. Sheterline P. Matrix Metalloproteinases and TIMPs. 2000;Oxford University Press, Oxford. This recently published book gives a comprehensive and up-to-date overview of the sequences, structures, biochemistry and biological functions of MMPs and TIMPs.
6. Konttinen Y.T., Ceponis A., Takagi M., Ainola M., Sorsa T., Sutinen M.E., Salo T., Ma J., Santavirta S., Seiki M. New collagenolytic enzymes cascade identified at the pannus-hard tissue junction in rheumatoid arthritis: destruction from above. Matrix Biol. 17:1998;585-601.
7. Ohuchi E., Imai K., Fujii Y., Sato H., Seiki M., Okada Y. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem. 272:1997;2446-2451.
8. Clark I.M., Powell L.K., Ramsey S., Hazleman B.L., Cawston T.E. The measurement of collagenase, tissue inhibitor of metalloproteinases (TIMP), and collagenase-TIMP complex in synovial fluids from patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum. 36:1993;372-379.
9. Mort J.S., Dodge G.R., Roughley P.J., Liu J., Finch S.J., DiPasquale G., Poole A.R. Direct evidence for active metalloproteinases mediating matrix degradation in interleukin 1-stimulated human articular cartilage. Matrix. 13:1993;95-102.
10. Dodge G.R., Pidoux I., Poole A.R. The degradation of type II collagen in rheumatoid arthritis: an immunoelectron microscopic study. Matrix. 11:1991;330-338.
11. McCachren S.S. Expression of metalloproteinases and metalloproteinase inhibitor in human arthritic synovium. Arthritis Rheum. 34:1991;1085-1093.
12. Billinghurst R.C., Dahlberg L., Ionescu M., Reiner A., Bourne R., Rorabeck C., Mitchell P., Hambor J., Diekmann O., Tschesche H., et al. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest. 99:1997;1534-1545.
13. Tetlow L.C., Woolley D.E. Comparative immunolocalization studies of collagenase 1 and collagenase 3 production in the rheumatoid lesion, and by human chondrocytes and synoviocytes in vitro. Br J Rheumatol. 37:1998;64-70.
14. Konttinen Y.T., Ainola M., Valleala H., Ma J., Ida H., Mandelin J., Kinne R.W., Santavirta S., Sorsa T., López-Otín C., et al. Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann Rheum Dis. 58:1999;691-697. This report gives a comparative profile of MMP expression in physiological tissue remodelling and inflammatory tissue destruction, revealing some important differences.
15. Dahlberg L., Billinghurst R.C., Manner P., Nelson F., Webb G., Ionescu M., Reiner A., Tanzer M., Zukor D., Chen J., et al. Selective enhancement of collagenase-mediated cleavage of resident type II collagen in cultured osteoarthritic cartilage and arrest with a synthetic inhibitor that spares collagenase 1 (matrix metalloproteinase 1). Arthritis Rheum. 43:2000;673-682. The authors demonstrate inhibition of type II collagen loss from osteoarthritic cartilage by a new synthetic MMP inhibitor, RS-102481, which spares MMP-1 but is effective against MMP-13. It also demonstrates that collagen loss from osteoarthritic cartilage in vitro is increased compared to normal cartilage and occurs in the absence of proteoglycan loss.
16. Killar L., White J., Black R., Peschon J. Adamalysins: a family of metzincins including TNF-α converting enzyme (TACE). Ann NY Acad Sci. 878:1999;442-452.
17. Tortorella M.D., Burn T.C., Pratta M.A., Abbaszade I., Hollis J.M., Liu R., Rosenfeld S.A., Copeland R.A., Decicco C.P., Wynn R., et al. Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science. 284:1999;1664-1666.
18. Abbaszade I., Liu R.Q., Yang F., Rosenfeld S.A., Ross O.H., Link J.R., Ellis D.M., Tortorella M.D., Pratta M.A., Hollis J.M., et al. Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family. J Biol Chem. 274:1999;23443-23450.
19. Billington C.J., Clark I.M., Cawston T.E. An aggrecan-degrading activity associated with chondrocyte membranes. Biochem J. 336:1998;207-212.
20. Black R.A., Rauch C.T., Kozlosky C.J., Peschon J.J., Slack J.L., Wolfson M.F., Castner B.J., Stocking K.L., Reddy P., Srinivasan S., et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature. 385:1997;729-735.
21. Amour A., Slocombe P.M., Webster A., Butler M., Knight C.G., Smith B.J., Stephens P.E., Shelley C., Hutton M., Knäuper V., et al. TNF-α converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett. 435:1998;39-44.
22. Kashiwagi M., Tortorella M., Nagase H., Brew K.: TIMP-3 is a potent inhibitor of ADAM-TS4 (aggrecanase 1) and ADAM-TS5 (aggrecanase 2). J Biol Chem 2001, in press.
23. Beckett R.P., Whittaker M. Matrix metalloproteinase inhibitors 1998. Exp Opin Ther Pat. 8:1998;259-282.
24. Bode W., Fernandez-Catalan C., Tschesche H., Grams F., Nagase H., Maskos K. Structural properties of matrix metalloproteinases. Cell Mol Life Sci. 55:1999;639-652.
25. Shapiro S.D. Mighty mice: transgenic technology 'knocks out' questions of metalloproteinase function. Matrix Biol. 15:1997;527-533.
26. MacPherson L.J., Bayburt E.K., Capparelli M.P., Carroll B.J., Goldstein R., Justice M.R., Zhu L.J., Hu S.I., Melton R.A., Fryer L., et al. Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J Med Chem. 40:1997;2525-2532.
27. O'Byrne E.M., Blancuzzi V., Singh H., MacPherson L.J., Parker D.T., Roberts E.D. Chondroprotective activity of a matrix metalloproteinase inhibitor, CGS 27023A in animal models of osteoarthritis. Tanaka S., Hamanishi C. Advances in Osteoarthritis. 1999;5 Springer-Verlag, Tokyo.
28. Chau T., Jolly G., Plym M.J., McHugh M., Bortolon E., Wakefield J., Gianpaolo-Ostravage G., Maniglia C. Inhibition of articular cartilage degradation in dog and guinea pig models of osteoarthritis by the stromelysin inhibitor, BAY 12-9566 [abstract]. Arthritis Rheum. 41:(Suppl):1998;S300.
29. Leff R.L. Clinical trials of a stromelysin inhibitor. Ann NY Acad Sci. 878:1999;201-207.
30. Brewster M., Lewis E.J., Wilson K.L., Greenham A.K., Bottomley K.M.K. Ro-32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the STR/ORT mouse model of osteoarthritis. Arthritis Rheum. 41:1998;1639-1644.
31. Brown P.D. Clinical studies with matrix metalloproteinase inhibitors. Acta Pathol Microbiol Immunol Scand. 107:1999;174-180.
32. Drummond A.H., Beckett P., Brown P.D., Bone E.A., Davidson A.H., Galloway W.A., Gearing A.J.H., Huxley P., Laber D., McCourt M., et al. Preclinical and clinical studies of MMP inhibitors in cancer. Ann NY Acad Sci. 878:1999;228-235.
33. Bayer drug casts shadow over MMP inhibitors in cancer. Scrip 1999, 24767.
34. Billinghurst R.C., Wu W., Ionescu M., Reiner A., Dahlberg L., Chen J., van Wart H., Poole A.R. Comparison of the degradation of type II collagen and proteoglycan in nasal and articular cartilages induced by interleukin-1 and the selective inhibition of type II collagen cleavage by collagenase. Arthritis Rheum. 43:2000;664-672. The authors demonstrate the measurement of collagenase-generated type II collagen cleavage neoepitopes and use this technique to show the efficacy of RS-102481 in preventing collagen loss from bovine cartilage in vitro. This technique may be useful for monitoring cartilage collagen damage in vivo as an alternative to radiological progression.
35. Yamada A., Uegaki A., Nakamura T., Ogawa K. ONO-4817, an orally active matrix metalloproteinase inhibitor, prevents lipopolysaccharide-induced proteoglycan release from the joint cartilage in guinea pigs. Inflamm Res. 49:2000;144-146.
36. Teronen O., Heikkila P., Konttinen Y.T., Laitinen M., Salo T., Hanemaaijer R., Teronen A., Maisi P., Sorsa T. MMP inhibition and downregulation by bisphosphonates. Ann NY Acad Sci. 878:1999;453-465. This covers the in vitro inhibitory effect of different bisphosphonates on the catalytic activity of several MMPs, including the collagenases.
37. Greenwald R.A., Kirkwood K. Adult periodontitis as a model for rheumatoid arthritis. J Rheumatol. 26:1999;1650-1653.
38. Ashley R.A. Clinical trials of a matrix metalloproteinase inhibitor in human periodontal disease. Ann NY Acad Sci. 878:1999;335-346.
39. Nordstrom D., Lindy O., Lauhio A., Sorsa T., Santavirta S., Konttinen Y.T. Anti-collagenolytic mechanism of action of doxycycline treatment in rheumatoid arthritis. Rheumatol Int. 17:1998;175-180.
40. Firestein G.S., Manning A.M. Signal transduction and transcription factors in rheumatic disease. Arthritis Rheum. 42:1999;609-621. This excellent review describes different classes of transcription factors and signal transduction pathways in the context of rheumatic disease.
41. Su B., Karin M. Mitogen-activated protein kinase cascades and the regulation of gene expression. Curr Opin Immunol. 8:1996;402-411.
42. Bondeson J., Brennan F., Foxwell B., Feldmann M. Effective adenoviral transfer of IκBα into human fibroblasts and chondrosarcoma cells reveals that the induction of matrix metalloproteinases and proinflammatory cytokines is nuclear factor-κB dependent. J Rheumatol. 27:2000;2078-2089.
43. Bondeson J., Foxwell B., Brennan F., Feldmann M. Defining therapeutic targets by using adenovirus: blocking NF-κB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators. Proc Natl Acad Sci USA. 96:1999;5668-5673. The authors provide evidence that blockade of NFκB is beneficial in the rheumatoid joint, reducing both inflammation and tissue destruction.
44. Ridley S.H., Sarsfield S.J., Lee J.C., Bigg H.F., Cawston T.E., Taylor D.J., DeWitt D.L., Saklatvala J. Actions of IL-1 are selectively controlled by p38 mitogen-activated protein kinase. J Immunol. 158:1997;3165-3173.
45. Mengshol J.A., Vincenti M.P., Coon C.I., Barchowsky A., Brinckerhoff C.E. Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor κB. Arthritis Rheum. 43:2000;801-811. The authors show that IL-1 induction of MMP-13 in chondrocytes involves multiple pathways, and that MMP-1 and MMP-13 are differentially regulated by IL-1.
46. Han Z., Boyle D.L., Chang L., Manning A.M., Karin M., Firestein G.S. c-Jun N-terminal kinase is required for metalloproteinase (MMP) expression in synoviocytes and regulates bone destruction in adjuvant arthritis. Arthritis Rheum. 43:2000;S398.
47. Tak P.P., Hart B.A., Kraan M.C., Jonker M., Smeets T.J.M., Breedveld F.C. The effects of interferon beta treatment on arthritis. Rheumatol. 38:1999;362-369.
48. Triantaphyllopoulos K.A., Williams R.O., Tailor H., Chernajovsky Y. Amelioration of collagen-induced arthritis and suppression of interferon-γ, interleukin-12, and tumor necrosis factor α production by interferon-β gene therapy. Arthritis Rheum. 42:1999;90-99.
49. 2 from human synovial fibroblasts. The authors demonstrate the potential of IFNβ therapy to decrease both joint inflammation and joint destruction.
50. van Lent P.L., Blom A.B., Lubberts E., Holthuysen A.E.M., van den Berg W.B. Protection against metalloproteinase-induced cartilage damage during immune complex-mediated arthritis by local IL-4 gene therapy. Arthritis Rheum. 43:2000;S273.
51. Cleaver C., Rowan A.D., Cawston T.E. IL-13 blocks the release of collagen fragments from bovine nasal cartilage treated with proinflammatory cytokines by preventing procollagenase activation. Ann Rheum Dis. 60:2001;150-157. The chondroprotective effect of IL-13 in cartilage explant culture is demonstrated for the first time in this report.
52. Ghosh P. The pathobiology of osteoarthritis and the rationale for the use of pentosan polysulfate for its treatment. Semin Arthritis Rheum. 28:1999;211-267.
53. Takizawa M., Ohuchi E., Yamanaka H., Nakamura H., Ikeda E., Ghosh P., Okada Y. Production of tissue inhibitor of metalloproteinases 3 is selectively enhanced by calcium pentosan polysulfate in human rheumatoid synovial fibroblasts. Arthritis Rheum. 43:2000;812-820. The authors demonstrate selective stimulation of TIMP-3 protein production by calcium pentosan polysulfate in human rheumatoid synovial fibroblasts, with no concomitant effects on MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, and MMP-13 or on TIMP-1, TIMP-2 or TIMP-4. In rheumatoid synovium, the induced TIMP-3 was found mainly in the hyperplastic lining cells.
54. Akimoto H., Yamazaki R., Hashimoto S., Sato T., Ito A. 4′-hydroxy aceclofenac suppresses the interleukin-1-induced production of promatrix metalloproteinases and release of sulfated-glycosaminoglycans from rabbit articular chondrocytes. Eur J Pharmacol. 401:2000;429-436.
55. Yamada H., Watanabe K., Saito T., Hayashi H., Niitani Y., Kikuchi T., Ito A., Fujikawa K., Lohmander L.S. Esculetin (dihydroxycoumarin) inhibits the production of matrix metalloproteinases in cartilage explants, and oral administration of its prodrug, CPA-926, suppresses cartilage destruction in rabbit experimental osteoarthritis. J Rheumatol. 26:1999;654-662.
56. Elliott S., Rowan A.D., Carrère S., Koshy P., Catterall J.B., Cawston T.E. Esculetin inhibits cartilage resorption induced by interleukin 1α in combination with oncostatin M. Ann Rheum Dis. 60:2001;158-165.
57. Brennan F.M., Browne K.A., Green P.A., Jaspar J.M., Maini R.N., Feldmann M. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-α (cA2) therapy. Br J Rheumatol. 36:1997;643-650.
58. Maini R., St Clair E.W., Breedveld F., Furst D., Kalden J., Weisman M., Smolen J., Emery P., Harriman G., Feldmann M., Lipsky P. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 354:1999;1932-1939.
59. van den Berg W.B., Joosten L.A.B., van de Loo F.A.J. TNFα and IL-1β are separate targets in chronic arthritis. Clin Exp Rheumatol. 17:1999;S105-S114.